Provided by Tiger Fintech (Singapore) Pte. Ltd.

Scilex Holding Company

6.02
-0.1000-1.63%
Post-market: 5.74-0.2763-4.59%18:58 EDT
Volume:108.77K
Turnover:655.64K
Market Cap:41.54M
PE:-9.88
High:6.32
Open:6.06
Low:5.80
Close:6.12
Loading ...

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Kds2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (Ad) Currently Enrolling With U.S. Patient Cohort to Be Added in 2025

THOMSON REUTERS
·
12 Dec 2024

BRIEF- KDS2010 Shows Promising Preclinical Results In Obesity Treatment

Reuters
·
11 Dec 2024

Scilex Holding Co - Kds2010 Reduced Obesity in Mice Without Suppressing Appetite

THOMSON REUTERS
·
11 Dec 2024

SCLX Gets Exclusive Rights to Important Drug

Zacks Small Cap Research
·
10 Dec 2024

Neurobiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company Enter Into Binding Term Sheet for Worldwide License, Along With the Rights to Sublicense for All of Kds2010 Indications; Binding Term Sheet Includes Collaboration for Development and Commercialization of Novel Oral Tablet Kds2010 in Ongoing Phase 2 Cardiometabolic and Neurodegenerative Diseases

THOMSON REUTERS
·
10 Dec 2024

Scilex Holding Co - Scilex Bio to Advance Kds2010 in Phase 2 Trials for Obesity and Alzheimer's

THOMSON REUTERS
·
10 Dec 2024

Scilex Holding Co: Ipmc Will Own 40% of Jv Upon Contribution of Exclusive, Perpetual and Worldwide Rights to Kds2010 Compound for All Indications

THOMSON REUTERS
·
10 Dec 2024

Scilex Holding Company Enters Into a Binding Term Sheet for a Joint Venture With Ipmc and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-in-Class Novel Oral Tablet for the Treatment of Obesity and Neurodegenerative Diseases Including Alzheimer’s Disease

THOMSON REUTERS
·
10 Dec 2024

Scilex Holding Co: Co to Own Controlling Interest of Scilex Bio Jv Upon Contribution of $50 Mln of Semnur Pharmaceuticals, Common Stock Owned by Co

THOMSON REUTERS
·
10 Dec 2024

Scilex Gets Nasdaq's Noncompliance Notification

MT Newswires Live
·
22 Nov 2024

Scilex Holding Company Announces Receipt of Notice From Nasdaq

THOMSON REUTERS
·
22 Nov 2024

BRIEF-Scilex Holding Co - Expects Nasdaq Notice For Non-Compliance Due To Q3 Form 10-Q Delay - SEC Filing

Reuters
·
20 Nov 2024

Scilex Holding Said Ernst & Young Requested Audit Committee Investigation Into Contracts From June And September 2024; On November 19, 2024 The Audit Committee Determined To Dismiss EY, Effective Immediately

Benzinga
·
20 Nov 2024

Scilex Holding Co - Dismisses Ey as Accounting Firm Due to Inability to Provide Assurance Regarding Completion of Review of Q3 Results

THOMSON REUTERS
·
20 Nov 2024

Scilex Holding Co - Audit Committee Investigates June and September 2024 Contracts

THOMSON REUTERS
·
20 Nov 2024

Scilex Holding Co - Expects Nasdaq Notice for Non-Compliance Due to Q3 Form 10-Q Delay

THOMSON REUTERS
·
20 Nov 2024

Private companies who have a significant stake must be disappointed along with institutions after Scilex Holding Company's (NASDAQ:SCLX) market cap dropped by US$22m

Simply Wall St.
·
12 Nov 2024

Denali Capital Acquisition Extends Deadline to Complete Initial Business Combination

MT Newswires Live
·
12 Nov 2024

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

THOMSON REUTERS
·
12 Nov 2024

Scilex Holding Co -on Nov 1, Got Letter From Nasdaq Notifying Co Failure to Satisfy a Continued Listing Rule or Standard

THOMSON REUTERS
·
08 Nov 2024